文献速递重症综合管理与镇静镇痛复苏、休克与脓毒症

ICU入院时免疫抑制与ICU获得性细菌血流感染发生率无关:COCONUT研究

Immunosuppression at ICU admission is not associated with a higher incidence of ICU-acquired bacterial bloodstream infections: the COCONUT study.
PubMed 文献 · Ann Intensive Care · 2024-06-05
一句话结论ICU入院时免疫抑制患者的28天ICU获得性细菌血流感染累积发生率与非免疫抑制患者无统计学差异。

这项在法国里尔大学附属医院ICU进行的回顾性单中心队列研究,纳入2020年1月1日至12月31日期间住院超过48小时的全部成年患者,共1313例(男性66.9%,中位年龄62岁),其中271例(20.6%)在ICU入院时存在免疫抑制。主要目标是比较免疫抑制与非免疫抑制患者28天ICU获得性细菌血流感染的累积发生率,次要目标是比较两组微生物学特征和结局。结果显示,无论调整预设基线混杂因素前后,两组28天累积发生率均无统计学差异;细菌分布相似,革兰阴性杆菌约占64.1%,多重耐药菌比例也相似;发生ICU获得性细菌血流感染与更长的ICU住院时间和更长的有创机械通气时间相关,与死亡率无显著关联,免疫状态未改变这种关联。

要点

  • 免疫抑制组271例(20.6%)与非免疫抑制组相比,28天ICU获得性细菌血流感染累积发生率在调整前后均无统计学差异。
  • 两组细菌分布相似,革兰阴性杆菌约占64.1%,多重耐药菌比例也相似。
  • 发生ICU获得性细菌血流感染与更长的ICU住院时间和更长的有创机械通气时间相关,与死亡率无显著关联。
  • 免疫状态未改变ICU获得性细菌血流感染与上述结局之间的关联。
  • 两组入院时严重程度评分、有创设备使用和ICU期间抗生素暴露情况相当。

适用人群与场景

  • 法国里尔大学附属医院ICU在2020年1月1日至12月31日期间住院超过48小时的全部成年患者,无论免疫状态如何。

诊断标准与关键阈值

  • 免疫抑制定义为活动性癌症或血液系统恶性肿瘤、中性粒细胞减少、造血干细胞和实体器官移植、使用类固醇或免疫抑制药物、人类免疫缺陷病毒感染和遗传性免疫缺陷。

研究设计与关键结果

  • 回顾性单中心队列研究,共纳入1313例患者(男性66.9%,中位年龄62岁),其中271例(20.6%)在ICU入院时存在免疫抑制。
  • 两组入院时严重程度评分、有创设备使用和ICU期间抗生素暴露情况相当。
  • 调整预设基线混杂因素前后,免疫抑制与非免疫抑制患者28天ICU获得性细菌血流感染累积发生率均无统计学差异。
  • 两组细菌分布相似,革兰阴性杆菌约占64.1%,多重耐药菌比例也相似。
  • 发生ICU获得性细菌血流感染与更长的ICU住院时间和更长的有创机械通气时间相关,与死亡率无显著关联;免疫状态未改变这种关联。

证据类型、等级与局限

  • 证据类型:回顾性单中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 对于ICU入院时存在免疫抑制的患者,不应仅基于免疫状态而预期其ICU获得性细菌血流感染发生率更高;两组28天累积发生率无统计学差异。
  • 免疫抑制状态未改变ICU获得性细菌血流感染与更长ICU住院时间、更长有创机械通气时间的关联,也未改变其与死亡率无显著关联的结论。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Immunosuppression at intensive care unit (ICU) admission has been associated with a higher incidence of ICU-acquired infections, some of them related to opportunistic pathogens. However, the association of immunosuppression with the incidence, microbiology and outcomes of ICU-acquired bacterial bloodstream infections (BSI) has not been thoroughly investigated.

METHODS: Retrospective single-centered cohort study in France. All adult patients hospitalized in the ICU of Lille University-affiliated hospital for > 48 h between January 1st and December 31st, 2020, were included, regardless of their immune status. Immunosuppression was defined as active cancer or hematologic malignancy, neutropenia, hematopoietic stem cell and solid organ transplants, use of steroids or immunosuppressive drugs, human immunodeficiency virus infection and genetic immune deficiency. The primary objective was to compare the 28-day cumulative incidence of ICU-acquired bacterial BSI between immunocompromised and non-immunocompromised patients. Secondary objectives were to assess the microbiology and outcomes of ICU-acquired bacterial BSI in the two groups.

RESULTS: A total of 1313 patients (66.9% males, median age 62 years) were included. Among them, 271 (20.6%) were immunocompromised at ICU admission. Severity scores at admission, the use of invasive devices and antibiotic exposure during ICU stay were comparable between groups. Both prior to and after adjustment for pre-specified baseline confounders, the 28-day cumulative incidence of ICU-acquired bacterial BSI was not statistically different between immunocompromised and non-immunocompromised patients. The distribution of bacteria was comparable between groups, with a majority of Gram-negative bacilli (~ 64.1%). The proportion of multidrug-resistant bacteria was also similar between groups. Occurrence of ICU-acquired bacterial BSI was associated with a longer ICU length-of-stay and a longer duration of invasive mechanical ventilation, with no significant association with mortality. Immune status did not modify the association between occurrence of ICU-acquired bacterial BSI and these outcomes.

CONCLUSION: The 28-day cumulative incidence of ICU-acquired bacterial BSI was not statistically different between patients with and without immunosuppression at ICU admission.

来源:Ann Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Zebian G, Kreitmann L, Houard M, et al. Immunosuppression at ICU admission is not associated with a higher incidence of ICU-acquired bacterial bloodstream infections: the COCONUT study. Ann Intensive Care. 2024. PMID: 38837065. doi:10.1186/s13613-024-01314-1

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。